MedTrace Logo

PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis

NCT02955966 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-11-20

No results posted yet for this study

Summary

OPTIFIL is a pilot prospective multicenter study based over the hypothesis that the normalization of the functional imaging 18F-FDG-PET/CT during the Invasive pulmonary aspergillosis (IPA) could occur earlier than that of conventional imaging.

This study evaluates the therapeutic response through a systematic 18F-FDG-PET/CT at week 6. The latter response will be correlated with the kinetics of selected biomarkers including antigens (galactomannan, β-D glucans), circulating Aspergillus DNA and anti-Aspergillus host response markers in addition to the conventional imaging tools obtained at weeks 6 and 12.

Conditions

  • Aspergillosis and Haematological Malignancy

Interventions

DEVICE

imaging 18F-FDG-PET/CT

18F-FDG PET Scan at Day 0, W6 and W12

BIOLOGICAL

Blood collection

Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.

Sponsors & Collaborators

  • Institut Pasteur, Paris France

    collaborator UNKNOWN

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Fanny LANTERNIER, Md, PhD · Assistance Publique - Hôpitaux de Paris

  • Olivier LORTHOLARY, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-02
Primary Completion
2022-05-02
Completion
2022-05-02

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02955966 on ClinicalTrials.gov